JAMA
LightNews LightNews
banner
jama.com
JAMA
@jama.com
22K followers 110 following 2.3K posts
JAMA is an international peer-reviewed general medical journal and a member of the JAMA Network family of journals.

🌐 JAMA.com
Posts Replies Media Videos
jama.com
💬 Viewpoint: The One Big Beautiful Bill Act institutes new federal loan caps for medical students, increasing debt burden risks and barriers for aspiring physicians.

ja.ma/4qN1yxQ
JAMA editorial, published online November 10, 2025, discusses how federal loan caps burden medical students. Article by Katie Farkouh, Jacqueline Hogan, and Maxwell Barton addresses impacts of new loan limits.
November 10, 2025 at 5:30 PM
jama.com
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease that predominantly affects women ages 40 to 60 years.

💡 This JAMA Insights discusses the clinical presentation, diagnosis, and treatment of PBC.

ja.ma/43T7yeF
Published online November 10, 2025, JAMA Insights, Primary Biliary Cholangitis, by Michele M. Tana, MD, MHS; Gideon M. Hirschfield, MA, MBBChir, PhD. Figure. Primary Biliary Cholangitis (PBC)—From Diagnosis to Personalized Care.
November 10, 2025 at 5:15 PM
jama.com
"During the last two decades, the prevalence almost doubled."

Author Norbert Stefan, MD, from the University Hospital of Tübingen discusses metabolic dysfunction-associated steatotic liver disease (MASLD) with JAMA Deputy Editor Kristin Walter, MD, MS.

ja.ma/442IqlH
JAMA Clinical Reviews podcast cover with 'Diagnosis and Treatment of MASLD' title. Features a beige background with 'Clinical Reviews' text and a red 'JN' logo. The word 'JAMA' is vertically oriented on the left.
November 10, 2025 at 5:12 PM
jama.com
Metabolic dysfunction-associated steatotic liver disease, or #MASLD, is the common “noncommunicable disease you’ve probably never heard of.”

Read on to learn more about the push for greater awareness.
“How Many of You Have Heard of MASLD?”
This Medical News article discusses the relatively unknown condition called metabolic dysfunction–associated steatotic liver disease, or MASLD, which is thought to affect approximately a third of adul...
jamanetwork.com
November 10, 2025 at 4:56 PM
jama.com
The most common chronic liver disease worldwide, metabolic dysfunction–associated steatotic liver disease (MASLD) affects approximately 30% to 40% of the general adult population.

This Review summarizes the diagnosis, treatment, and prognosis of MASLD. ja.ma/3XiORgN
Figure outlines MASLD progression from healthy liver to cirrhosis/hepatic decompensation. Factors promoting MASLD include diet, insulin resistance; protective factors: physical exercise, socioeconomic status. Progression rates are shown. Text: JAMA, Published online November 10, 2025.
November 10, 2025 at 4:30 PM
jama.com
Viewpoint by FDA Commissioner of Food and Drugs Martin Makary, MD, MPH, et al: Labeling changes for estrogen and progestogen products now emphasize individualized care, updated risk communication, and differences across systemic vs topical therapies.

ja.ma/3JQqSm4
A JAMA article titled 'Updated Labeling for Menopausal Hormone Therapy' by Martin A. Makary et al., published online November 10, 2025. Article discusses estrogen replacement and FDA labeling changes for menopausal hormone therapy.
November 10, 2025 at 4:15 PM
jama.com
💬 Viewpoint: Safeguarding pathways for non-US international medical graduates (IMGs) is essential to addressing physician shortages and ensuring health care access in underserved regions.

ja.ma/43nn8it
A JAMA article cover dated September 25, 2025, titled "International Medical Graduates, Visa Disruptions, and the Future of the US Physician Workforce" by Natalia Solenkova, discussing J-1 visa processing vulnerabilities.
November 10, 2025 at 2:00 PM
jama.com
💬 Viewpoint: Increasing unionization among medical trainees highlights the complex interplay of financial pressures, working conditions, and educational goals in health care systems.

ja.ma/3JDXQpK
A page from JAMA, published September 25, 2025, titled 'Reflections on Medical Trainee Unions and Health Care Systems' by Peter J. Frederick et al. It discusses unionization trends, benefits, and the context within the healthcare ecosystem.
November 10, 2025 at 1:00 PM
jama.com
💬 Viewpoint: Medical education should shift from pattern recognition to critical thinking and pathophysiological reasoning to reduce diagnostic errors and adapt to #AI advancements. #MedEd

ja.ma/4oZM2wP
Flowchart comparing illness script-based vs. pathophysiological approaches to patient diagnosis. The script-based approach starts with symptoms like nocturnal respiratory distress and ends with diuretics, while the pathophysiological approach starts with hypoxemia, and ends with CPAP.
November 10, 2025 at 12:00 PM
jama.com
In this #AHA25 edition of the JAMA Editor’s Summary podcast, Gregory Curfman, MD, Philip Greenland, MD, and Robert Bonow, MD, MS, review key JAMA Network articles, including:

➡️ Coffee and #AFib,
➡️ DASH-patterned groceries,
➡️ Oral PCSK9 inhibitor enlicitide, and more.

🎧 Listen now: ja.ma/47MpAAj
Close-up of JAMA journals stacked. The covers feature 'JAMA' in bold letters. Below, text reads: 'From AHA: Coffee Consumption and Atrial Fibrillation, DASH-... JAMA Editors' Summary'. A purple 'Play' button is visible.
November 9, 2025 at 11:35 PM
jama.com
💾 Save this thread! Check out these key findings from today's JAMA, @jamacardiology.com, @jamainternalmed.com, and
@jamanetworkopen.com presentations at #AHA25. 🧵

Adding coronary CT angiography to traditional risk scores modestly improved prediction of first coronary events. ja.ma/4oyzvko
Four graphs from a JAMA article titled 'Coronary Computed Tomography Angiography in Prediction of First Coronary Events'. The graphs show 'Cumulative Incidence of Coronary Events', charting coronary event rates by CACS, SIS, stenosis, and calcification.
November 9, 2025 at 11:20 PM
jama.com
Robert Bonow, MD, MS, is celebrated at #AHA25. Dr Bonow, founding editor of JAMA Cardiology, marked 10 years as its Editor in Chief.
Robert Bonow, MD, MS, is celebrated at #AHA25. Robert Bonow, MD, MS, is celebrated at #AHA25.
November 9, 2025 at 11:02 PM
jama.com
💬 Editorial: While early detection and treatment may help some high-risk youth, the modeling study by Bellows et al suggests broader population approaches to lower LDL-C distribution may provide greater value and cost-effectiveness.

#AHA25 @ahascience.bsky.social

ja.ma/4oXdIT9
An editorial from JAMA, published online November 9, 2025, titled "Childhood Cholesterol Screening Is Not Cost-Effective" by Matthew W. Gillman, MD, SM. The article discusses controversies and recommendations for hypercholesterolemia screening in youths.
November 9, 2025 at 10:40 PM
jama.com
Sequential childhood or early adulthood screening for familial hypercholesterolemia may lower lifetime CVD risk, but is unlikely to be cost-effective unless ongoing follow-up for elevated cholesterol is widely implemented.

#AHA25 @ahascience.bsky.social

ja.ma/47KxqdX
The JAMA article presents cost-effectiveness outcomes for familial hypercholesterolemia screening in children. Two graphs compare sequential screening to usual care, stratified by LDL-C threshold, with cost-effectiveness scatterplot and acceptability curve.
November 9, 2025 at 10:35 PM
jama.com
💬 Editorial: The GoFresh trial showed home-delivered DASH groceries modestly lowered BP and LDL cholesterol in Black adults, but high costs and diet design limit broader impact.

#AHA25 @ahascience.bsky.social

ja.ma/4hLvh6i
An editorial from JAMA, published online November 9, 2025, titled "Medically Tailored Groceries for Blood Pressure Control: Promise, Progress, and Need for Optimal Design" by Dariush Mozaffarian, MD, DrPH. The article discusses food as medicine.
November 9, 2025 at 10:30 PM
jama.com
RCT: Home-delivered, low-sodium Dietary Approaches to Stop Hypertension (DASH) groceries and dietitian support temporarily improved blood pressure and LDL cholesterol in Black adults with high BP versus monetary support.

#AHA25 @ahascience.bsky.social

ja.ma/4oZ5JVI
Infographic summarizing a JAMA study on home-delivered groceries and blood pressure in Black adults. Key findings: DASH grocery delivery resulted in -5.7 mm Hg change, self-directed shopping -2.3 mm Hg. The between-group difference was -3.4 mm Hg.
November 9, 2025 at 10:25 PM
jama.com
💬 Editorial: The CORALreef HeFH trial demonstrated that oral enlicitide achieves robust, sustained reductions in LDL-C and other atherogenic lipids in patients w/ heterozygous familial hypercholesterolemia receiving statin therapy.

#AHA25 @ahascience.bsky.social

ja.ma/4otLaAL
JAMA article: 'Beyond Statins—Expanding the Arsenal of Lipid-Lowering Therapies' by Michelle L. O'Donoghue et al., published online November 9, 2025. Article discusses statins and new therapies for reducing cardiovascular risk.
November 9, 2025 at 10:20 PM
jama.com
Among adults with HeFH who were already taking statin therapy, treatment with enlicitide was well tolerated and reduced levels of LDL-C, apolipoprotein B, non–HDL-C, and lipoprotein(a).

#AHA25 @ahascience.bsky.social

ja.ma/3WNXRKG
JAMA study: Oral PCSK9 inhibitor enlicitide reduces LDL cholesterol in adults with heterozygous familial hypercholesterolemia. 303 patients randomized, enlicitide group saw -58.2% change, placebo 2.6%.
November 9, 2025 at 10:15 PM
jama.com
Adding coronary CT angiography to traditional risk scores modestly improved prediction of first coronary events in a large population-based study.

#AHA25 @ahascience.bsky.social

ja.ma/3JOedjo
JAMA article graphs showing cumulative coronary event rates over time. Graphs detail rates by CACS, SIS, stenosis, and calcification, comparing different levels and conditions. Higher CACS/SIS scores and stenosis percentages correlate with increased event rates.
November 9, 2025 at 6:30 PM
Reposted by JAMA
erictopol.bsky.social
Get this: Coffee suppressed atrial fibrillation!
Unexpected results for recurrence from a randomized trial in participants after cardioversion from AF
#AHA25 @jama.com
jamanetwork.com/journals/jam...
November 9, 2025 at 2:51 PM
jama.com
A randomized clinical trial published in JAMA found that patients with AF who consumed caffeinated coffee had a lower risk of recurrent AF or atrial flutter compared with those who abstained.

#AHA25 #AFib @ahascience.bsky.social

ja.ma/47vUbDB
November 9, 2025 at 5:00 PM
jama.com
📊 Research Summary: Adults with #AFib who drank at least one cup of caffeinated coffee daily after successful cardioversion had a lower risk of recurrence than those who abstained from coffee and caffeine.

#AHA25 @ahascience.bsky.social

ja.ma/4nLL5r0
JAMA Research Summary: Caffeinated coffee consumption or abstinence to reduce atrial fibrillation. Coffee consumption had a 47% rate of recurrence of atrial flutter while coffee abstinence had a 64% rate over 6 months.
November 9, 2025 at 3:15 PM
jama.com
RCT: Patients with #AFib who continued their usual caffeinated coffee intake after cardioversion experienced less recurrence of AF or atrial flutter compared to those who abstained from coffee and caffeine.

#AHA25 @ahascience.bsky.social

ja.ma/47FZkaR
Infographic titled JAMA, it discusses the effect of caffeinated coffee on recurrent atrial fibrillation (AF). The study with 200 patients, found less AF recurrence with coffee vs abstinence. Coffee: 47% recurrence. Abstinence: 64%.
November 9, 2025 at 3:00 PM
jama.com
"[I]t will be critical to maintain a human in the loop even as we seek to incorporate the strengths of #AI-based review in our editorial process."

Read this Editorial from the editors and staff of JAMA and the JAMA Network journals.

ja.ma/4oXjl3H
An article titled "Artificial Intelligence in Peer Review" published in JAMA on August 28, 2025. The article discusses the role of AI in peer review, noting AI's potential to automate tasks but also warning of biases.
November 9, 2025 at 2:00 PM
jama.com
🧵 #AHA25 attendees, check out these key findings from today's JAMA and @jamacardiology.com presentations:

Among people with PAD and no #diabetes, metformin treatment for 6 months did not result in improvements in walking ability or secondary outcomes vs placebo. ja.ma/4oqMJzr
November 9, 2025 at 2:25 AM